 |
1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one |
|---|---|
| Trade Name | |
| Orphan Indication | Management of postherpetic neuralgia |
| USA Market Approval | USA |
| USA Designation Date | 2013-09-26 00:00:00 |
| Sponsor | Zalicus Pharmaceuticals Ltd.;245 First Street;Cambridge, Massachusetts, 02142 |
